AAN 2023: Radicava leads to better long-term survival in ALS
Radicava (edaravone) significantly prolongs long-term survival for people with amyotrophic lateral sclerosis (ALS), according to an analysis of…
Articles by Marisa Wexler, MS
AAN 2023: ALS treatments ID’d in HEALEY head toward Phase 3 tests
It’s been nearly three years since the HEALEY platform clinical trial started and, so far, two promising experimental treatments for…
AAN 2023: DNL343 is safe, appears to work as intended in Phase 1 trial
Treatment with the investigational therapy DNL343 was generally well-tolerated among people with amyotrophic lateral sclerosis (ALS) in an early…
Colder temperatures help cells to clear toxic proteins tied to ALS
Cold temperatures can activate a complex called the proteasome that cells use to clear themselves of unneeded proteins, including the…
AIT-101 clears toxic protein clumps, early data show
AI Therapeutics‘ experimental therapy AIT-101 led to reductions in levels of toxic proteins in people with amyotrophic lateral…
Expanded access program for SLS-005 begins treating first ALS patient
An expanded access program for the experimental treatment SLS-005 has dosed its first participant, according to…
Study links abnormal RNA modifications to TDP-43 function
TDP-43, a protein that is known to have toxic effects in amyotrophic lateral sclerosis (ALS), is able to interact…
MDA 2023: Issues with ALS scale scores noted in NurOwn trial failure
Difficulties in measuring the progression of amyotrophic lateral sclerosis (ALS) among patients with advanced disease can cause complications in…
MDA 2023: Designer DNA drug for ALS shows promise in mouse studies
In most cases of amyotrophic lateral sclerosis (ALS), dysfunction of a protein known as TDP-43 leads to abnormally low…
MDA 2023: Patients typically need wheelchairs within 2 years of onset
On average, a person with amyotrophic lateral sclerosis (ALS) will require a wheelchair to get around within two years…